Recent Updates
Recently added Catalysts
FATE

FT839: A Multi-Antigen Targeting Off-the-Shelf Dual-CAR T Cell for the Treatment of Pathogenic B and T Cells in Autoimmune Diseases

Wednesday, June 3, 2026 1 min read
Key Takeaway: The article discusses FT839, a novel dual-CAR T cell therapy designed to target pathogenic B and T cells in autoimmune diseases. It highlights the potential of this off-the-shelf treatment approach. However, specific details about clinical trials or results are not provided.
Price reaction · baseline $2.345 (2026-06-03T15:56:00.000Z) · hit during market hours · 2 other FATE headline(s) in the window, move may be shared
day 0 close
-5.3%
day 1
-5.8%
day 3 · peak
-18.6%

Market Sentiment Analysis

Full Press Release Details

• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Tags: FATE Viatris Investor Conferences Healthcare FT839 dual-CAR T cell autoimmune diseases pathogenic cells
Last updated: Jun 3, 2026

Biotech snapshot

Cash runway
$175M liquidity · $10M/mo burn
~15 mo
Low dilution risk
Lead asset
FT825Phase 1
Advanced Solid Tumor →

Catalyst track record

+215%
best trade around FATE's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for FATE.

See every catalyst's timing & PoA →